Get started
Work

Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH)

Year: 2024
Type: article
Study design: Observational Study
Abstract: Many adolescents with X-linked hypophosphatemia (XLH) currently have to stop treatment with burosumab at the end of skeletal growth. We describe the experience of a cohort of adolescents with XLH before, during, and after stopping burosumab (median treatment duration 37.5 months). Improvements in serum phosphate, pain, mobility, function, and quality of life noted during burosumab treatment were reversed after treatment cessation. Further real-world data are needed to explore the value of uninterrupted burosumab treatment in adolescents.
Source: Bone Reports
DOI: 10.1016/j.bonr.2024.101819
Authors: Charlotte Jarvis, Renuka Ramakrishnan, Poonam Dharmaraj, Talat Mushtaq, Sanjay Gupta, Angela Williams, Angela J. Rylands, Helen Barham, Annabel Nixon, Suma Uday
Institutions: Alder Hey Children's NHS Foundation Trust, Alder Hey Children's Hospital, Leeds Teaching Hospitals NHS Trust, University of Hull, Kyowa Kirin International (United Kingdom), Birmingham Women’s and Children’s NHS Foundation Trust
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,400
OpenAlex ID: W4404665664
FWCI: 1.756
Cites: 20
Cited by: 7
Related to: 10